varsetatug masetecan
Generic: Varseta-M·Code: Varseta-M
varsetatug masetecan: sourced relationships with 1 company · 1 clinical trial tracked.
varsetatug masetecan evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect varsetatug masetecan to CTMX; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could varsetatug masetecan → CTMX affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Solid Tumor, AdultColorectal cancer (CRC)
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| CytomX Therapeutics, Inc. (CTMX) Solid Tumor, Adult | Phase 1 |
| CytomX Therapeutics, Inc. (CTMX) | Phase 1 |
Clinical Trial Registry Records (1)
An Investigational Study of CX-2051 in Participants With Advanced Solid Tumors
Primary endpoint: Safety and tolerability of CX-2051
Interventionalopen160 targetStarted 2024-04Completion 2029-038 sites · United StatesCytomX Therapeutics
Frequently asked questions
Which companies have sourced relationships with varsetatug masetecan?
varsetatug masetecan has dated SEC/FDA relationship records for CytomX Therapeutics, Inc..
How many clinical trials involve varsetatug masetecan?
BioSniper tracks 1 clinical trial involving varsetatug masetecan.